Lantern Pharma Analyst Ratings
Lantern Pharma Analyst Ratings
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a initiated with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $4.19, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2022 | 162.53% | EF Hutton | → $11 | Initiates Coverage On | → Buy |
| 03/11/2022 | 759.19% | HC Wainwright & Co. | $34 → $36 | Maintains | Buy |
| 11/02/2021 | 711.46% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/07/2021 | 663.72% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 07/28/2020 | 472.79% | Colliers Securities | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/01/2022 | 162.53% | EF Hutton | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/11/2022 | 759.19% | HC Wainwright & Co. | 34 美元 → 36 美元 | 維護 | 買 |
| 11/02/2021 | 711.46% | HC Wainwright & Co. | 32 美元 → 34 美元 | 維護 | 買 |
| 2021 年 7 月 10 日 | 663.72% | HC Wainwright & Co. | → 32 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 7 月 28 日 | 472.79% | 高力證券 | → 24 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Lantern Pharma Questions & Answers
Lantern Pharma 問題與解答
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on November 1, 2022. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 162.53% upside). 3 analyst firms have reported ratings in the last year.
EF Hutton於2022年11月1日公佈了Lantern Pharma（納斯達克股票代碼：LTRN）的最新目標股價。該分析公司將目標股價定爲11.00美元，預計LTRN將在12個月內升至12個月內（可能上漲162.53％）。去年有3家分析公司公佈了評級。
The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma initiated their buy rating.
EF Hutton對Lantern Pharma（納斯達克股票代碼：LTRN）的最新分析師評級由EF Hutton提供，Lantern Pharma啓動了買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on November 1, 2022 so you should expect the next rating to be made available sometime around November 1, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Lantern Pharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Lantern Pharma的最新評級是在2022年11月1日公佈的，因此您應該預計下一個評級將在2023年11月1日左右公佈。
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a initiated with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $4.19, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Lantern Pharma（LTRN）評級已啓動，目標股價爲0.00美元至11.00美元。Lantern Pharma（LTRN）目前的交易價格爲4.19美元，在分析師的預測區間內。